original immunomodulator of new generation
Original natural product derived from cell walls Lactobacillus Delbrueckii using modern production technology
High efficiency has been proven in 8 multicenter clinical trials, which were conducted in leading scientific and medical institutions of Ukraine.
It has a pronounced immunomodulatory effect, contributes to the normalization of impaired immunity parameters, blood leukocytes.
Gives additional antitumor and antimetastatic effects, non-toxic, well tolerated by patients and, practically, does not cause side effects.
Provisional medical care in preparation therapy is taken, prepared for the newest technologies of virion technologies. The preparation LIASTEN© was developed by a large team of scientists and practitioners, is protected by several patents of Ukraine, and is issued by DP "ENZIM" (Ladyzhyn, Vinnytsia region, Ukraine).
It has been convincingly proven high efficacy and safety of the preparation. So, in 8 multicenter clinical studies that were conducted in leading scientific and medical institutions of Ukraine, it was found that LIASTEN© has a pronounced immunomodulatory effect, contributes to the normalization of impaired immunity parameters, blood leukocytes, gives additional antitumor and antimetastatic effects, exhibits radioprotective and antioxidant properties, helps cancer patients successfully complete a full course of chemotherapy and radiation therapy, increases the duration and quality of their life.
efficiency
The preparation LIASTEN© is prescribed as immunomodulating and haemoprotecting remedy at:
the diseases accompanying with a secondary immunodeficiency and leukopenia;
chemotherapy and radiotherapy of oncological patients and patients with leucosis;
hronic radiation injuries;
surgical treatment of oncological and other diseases of breast;
acute and chronic bacterial and viral infections, in particular for tuberculosis;
for the treatment of patients with leukopenia of different origin.
Advantages of the preparation LIASTEN©:
stimulates the work of all basic cells of immune system (Т- and B-lymphocytes, macrophages);
strengthens phagocytosis (absorption and digestion) of virus-infected, and tumoral cells, bacterial agents by the cells of immune system;
strengthens the production of protective antibodies against alien substances;
raises cytotoxinic properties of lymphocytes and other cells in relation to alien bacterial agents, to virus-infected and tumoral cells;
stimulates haemo- and leucopoiesis (process of blood leukocytes and erythrocytes formation);
reduces by-effects of chemotherapy and radiotherapy of tumours;
improves blood circulation in tissues, improves healing of postoperative wounds;
modulation of cytochrome P-450 system.
safety
conclusion
At the Institute of Oncology of Medical Sciences Academy of Ukraine in the department of radiotherapy the clinical studies have been conducted to study the effect of the medical immunobiological preparation Liasten in chemoradiation therapy (CRT) in cancer patients from April 1, 2007 until August 1, 2007.
According to the instructions for the preparation Liasten refers to immunomodulators of natural origin with a wide spectrum of action. It is a fragment of the cell wall of lactobacilli that stimulate the function of macrophages and normalizes the number of T-lymphocytes. Liasten is able to increase the cytotoxic activity of natural cells-killers, helps to stimulate leukopoiesis and reduces the side effects of chemotherapy and radiation therapy.
The study included patients with breast cancer II B-ShB st. and patients with cancer of the cervix and body of the uterus IB-SB st. The study group consisted of 20 patients: 6 - patients with breast cancer, 8 — cancer of the cervix and 6 - cancer of the uterus. The control group consisted of 10 patients: 4 - breast cancer and 6 - cancer of the cervix. All patients underwent CRT according to the standard treatment methods. During the entire course of treatment Liasten was administered to patients of the study group with the dosage 200 mg intramuscularly once every 7 days, with a maximum dose of 1000 mg per 5 injections.
All patients were well tolerated. With the introduction of Liasten hyperemia, hyperthermia and slight itching were observed in one patient at the place of injection. Under the influence of desensitizing drugs, all side effects have disappeared. The second patient of the study group had a headache after the injection, and in two of the remaining patients the body temperature increased to 37,5 °C during 5-6 hours after each injection, however, this did not require medical correction.
Starting with the 2-3rd injection of Liastenu on the background of CRT, patients noted the decrease of pain and weakness. During this period the reduction in the size of the tumor and the infiltration of surrounding normal tissues were recorded using objective research methods. Despite the fact that the patients of the group under study received radiation and chemotherapy, the indications of blood, namely leukocytes and lymphocytes during the entire course were within the normal range. In 6 patients of the control group, leukopenia was registered during treatment (5 cases – I degree, 1 case – II degree), 2 patients had thrombocytopenia. Radiation reactions (enterocolitis, epidermis) were also observed in the majority of patients in this group. Taken into account the severity of radiation reactions, 3 patients in the control group needed a forced interruption of treatment.
Thus, the use of Liasten in the treatment of cancer patients helps to stimulate leukopoiesis, reduces the side effects of CRT, makes it possible to conduct a course of treatment in the planned amount and without a forced break. Therefore, Liasten can be used in CRT of cancer patients as an accompanying preparation to ensure the full course of the main treatment.
Head of Radiation Therapy Department of Medical Sciences,
prof. Ivankova V.S.
Deputy Director for Science 10 ANU, MD,
prof. Grinevich Yu.Ya.
| name of study | main results |
|---|---|
| Institute of experimental oncology and radiobiology by R.E.Kavetskiy НАНУ, Kyiv, 1994. | |
| "Experimental studying of specific and general pharmacological activity of the substance and ГЛС of Blastolen". | Dozadepending smmunomodulation of cellular and humoral immunity, stimulation of haemopoiesis, functions of macrophages is proved. |
| Institute of pharmacology and toxicology АМНУ, Kyiv, 1994. | |
| ""Experimental studying of harmlessness of a substance and GLS of Blastolen". | Absence of sharp toxic, sensitizing and allergitising activity is proved. It is revealed dozadepending locally irritating action. |
| The Kyiv scientific research institute of epidemiology and infectious diseases by L.V.Gromashevskiy, Kyiv, 1995. | |
| "The results of clinical test (1-st phase) of preparation "Blasten" at patients with meningitoencephalitis and leptospirosis". | Absence of the expressed positive clinical effect, absence of the expressed by-effects of the preparation. |
| National medical university by A.A.Bogomolets, department of faculty surgery №1, Kyiv, 1996. | |
| "Clinical test of the new medical product immunomodulator "Blasten" (2-nd phase)". | Reduction of frequency of postoperative complications, improvement of regeneration of wounds, improvement of the general state. |
| Scientific research institute of oncology and radiology MH of Ukraine, Kyiv, 1996. | |
| "Clinical test of the new medical product immunomodulator "Blasten" (2-nd phase)". | Reduction of by-effects of chemo- and radiotherapy, immuno- modulating influence. |
| The Kyiv scientific research institute of otolaryngology МH of Ukraine, Kyiv, 1996. | |
| "Clinical test of the new medical product immunomodulator "Blasten" (2-nd phase)". | Reduction of by-effects of chemo- and radiotherapy, immuno- modulating influence. |
| Institute of experimental oncology and radiobiology by R.E.Kavetskiy НАНУ, Kyiv, 1996. | |
| "Clinical test of the new medical product immunomodulator "Blasten" (2-nd phase)". | Reduction of by-effects of chemo- and radiotherapy, immuno- modulating influence. |
| National medical university by A.A.Bogomolets, department of clinical immunology and allergology, Kyiv, 1999. | |
| "Studying of efficiency of "Blasten" clinical application in complex treatment of patients with chronic obstructive bronchitis". | Immunotropic action on a nonspecific part, phagocytosis, humoral immunity is proved, the scheme of application at ХОЗЛ is offered. |
| Note: since 2006 the formula of the preparation is produced by the company "Enzim" under the new commercial name LIASTEN©. | |
publications
Features of modern immunomodulatory therapy
Immunotropic preparations are remedies, the therapeutic effect of which is associated with the predominant (or selective) effect on the immune system. They include: immunomodulators (restoring immune system function, which depends on the initial state), immunostimulants, immunosuppressants...
Scientific journal ASTHMA AND ALLERGY January-March №1 2013.
Y.Feschenko, E.Rekalova
The National Institute of Tuberculosis and Pulmonology. F.G. Yanovsky NAMS of Ukraine, Kyiv
The results of treatment of patients with the newly diagnosed destructive pulmonary tuberculosis using muramilpeptide immunomodulator s. v.
Summary: The results of the complex treatment of patients with the newly diagnosed destructive pulmonary tuberculosis using original native muramilpeptide immunomodulator were analyzed. It was demonstrated that this immunomodulator positively influenced the state of monocytic-macrophage link of immunity, killer activity of lymphocytes and promoted the normalization of peripheral blood count in patients with pulmonary tuberculosis...
Ukrainian pulmonological magazine, №3 2010
S.V.Zaykov, O.V. Plikanchuk
Vinnitsa national medical university of Pirogov M.I.
The efficacy of treating patients with first diagnosed destructive pulmonary tuberculosis using immunomodulator of muramylpeptide series
Summary: The results of clinicolaboratory. immunologic and roentgenologic examination of muramylpeptide series immunomodulator efficacy in complex therapy of patients with first diagnosed destructive pulmonary tuberculosis are represented. Using original not imported immunomodulator LIASTEN contributed to the recovery of tuberculosis patients immune system condition and resulted in rapid dissapearance of main clinical symptoms...
Medications of Ukraine, №3(129) 2009
S.V.Zaykov, O.V. Plikanchuk
The dynamics of clinical and immunologic indices in patients with first diagnosed destructive lung tuberculosis using immunomodulator of muramylpeptide series
Summary: The resume of immunomodulator of muramylpeptide series effect on dynamics of immunologic indices in 40 patients with first diagnosed destructive lung tuberculosis were investigated. It was showed that after immunomodulating preparation use in the basic group the elevation of CD3+ T-lymphocytes, CD4+T-lymphocytes. CD16+ T-lymphocytes and towering of leucocyte hypersensitivity to tuberculin occurred. It is proved that the immunomodulator of muramylpeptide series stimulates protective immuno macroorganism response and accordingly improves efficacy of tuberculosis treatment...
Medical perspectives, 2009 volume XIV, 2
S.V.Zaykov, O.V. Plikanchuk
The dynamics of immunologic indices in patients with first diagnosed destructive lung tuberculosis using immuncmodulator of muramylpeptide series
Summary: Tuberculosis is the secondary immunodeficiency. At present the drugs positively influencing the immunologic mechanisms and accordingly improving the efficacy of treatment is widety used. The results of immunomodulator of muramylpeptide series effect on сlinical and immunologic indices in patients with first diagnosed destructive lung tuberculosis were investigated...
Tavricheskiy mediko-biologicheskiy vestnik, volume 12, № 1(45), 2009
S.V.Zaykov, O.V. Plikanchuk
Vinnitsa national medical university of the name of N.I.Pirogov
Prospects of application of immunomodulators at tuberculosis of respiratory apparatus
In the XXI century the tuberculosis continues to remain the global problem of humanity. According to the data of Worldwide organization of health protection (WOHP), general quantity of patients with tuberculosis makes 50-60 millions, annually 7-10 millions of new cases of tuberculosis are registered in the world, about 3 million persons die from it...
RATIONAL PHARMACOLOGY, №3(08), 2008
S.V.Zaykov, O.V. Plikanchuk
Vinnitsa national medical university of the name of N.I.Pirogov
Application of immunomodulators at diseases of respiratory apparatus
The perspective direction in the decision of this task is the development of the complex of the preventive actions, capable to affect the reduction of risk of development and frequency of relapses, synchronization, and also the severity of clinical course of infectious RAD, preventive maintenance of their complications, correction of secondary immune insufficiency (SII)...
RATIONAL PHARMACOLOGY, №1(06), 2008
S.V.Zaykov
Vinnitsa national medical university of the name of N.I.Pirogov
Prospects of application of immunomodulators of muramilpeptide line in oncology
Increase of treatment efficiency of patients with malignant neoplasms — one of the most actual problems of modern oncology. The basic methods of therapy of oncopathology (surgical operation, chemo- and radio therapy) are directed only on elimination of tumours, but are not capable to remove from the organism all tumor cells...
RATIONAL PHARMACOLOGY, №3(04), 2007, REVIEW
S.V.Zaykov, S.I. Shpilevaya
Results of immunological study of efficiency of the domestic immunomodulator liasten in complex treatment of patients with burns
Summary: In the work the results of immunological study of efficiency of the domestic immunomodulator Liasten in complex treatment of patients with severe burns are presented. The positive effect of Liasten use is achieved due to stimulation of cell and humoral components of immune system and tendency to normalization of natural resistance of the organism...
UDK: 615.37:615.065:616-001.17-059
V.I. Nagaichuk, S.V. Zaykov, A.M. Povoroznik, L.I. Moskalyova
Immunocorrection by an immunomodulator from laсtobacillus delbrueckii in a combined therapy of breast cancer at stages II to IV
Summary: The application of an immunomodulator produced by Laktobacillus Deibrueckii in a combined therapy of breast cancer at stages II to IV is shown to: favorably effect the cell content of peripheral blood: increase the activities of natural killer cells and phagocytosis, as well as spontaneous production of IL I. IL2, and TNF by peripheral blood monomuclears; and normalize the contents of IgA and CIC...
Oncology T.2 №4 2000
Z.D.Savtsova, S.I.Shpyleva, V.I.Tarurinov, V.P.Rogatska, T.A.Meniok, I.S.Nikolsky, V.S.Mosienko, L.M.Shynkarenko, V.F.Chekhun
Liasten: new original immunomodulator
Summary: Immune system (IS) of a person performs the important function on preservation of the constancy of the internal environment of an organism by recognition and removal from it viruses, bacteria, malignant cells and other alien substances...
Weekly journal APTEKA there is an article about preparation LIASTEN. Read in number №41 (562).
Sergey Zaykov
Blasten - new domestic immunomodulator of the biological origin
(It is submitted by acad. of NAS and АМS of Ukraine V. Frolkis) Results of beforeclinical studying of original medical preparation Blasten which is received from cellular walls Lactobacillus Delbrueckii are generalized. It is shown, that Blasten is an effective immunomodulator. The spectrum of Blasten immunomodulating effects includes: influence as on reaction of specific immunity, and nonspecific resistency of the organism...
Magazine АМS Ukraine, 1999, т. 5, №1. - С. 79-86 УДК. 615.32:615.37
V.S.Mosіenко, M.D.Mosіenко, 3. D.Savtsova, V.S.Danilenko, M.U.Volkova *, L.M.Shinkarenko, N.A.Shcheglova, V.G.Vospyakov, O.V.Svidro, Т. A.Menyok
faq
